However, a proportion of HER2+ GC patients do not respond to trastuzumab-containing front-line chemotherapy ab initio, progressing rapidly within 3–4 months, and displaying dismal prognosis despite treatment [3, 6]. Here, ERBB2 is linked to gastric cancer.